Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

The impact of the time to start radiation therapy on overall survival in newly diagnosed glioblastoma.

Santos VM, Marta GN, Mesquita MC, Lopez RVM, Cavalcante ER, Feher O.

J Neurooncol. 2019 May;143(1):95-100. doi: 10.1007/s11060-019-03137-8. Epub 2019 Mar 8.

PMID:
30850928
2.

Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles.

Barbagallo GM, Paratore S, Caltabiano R, Palmucci S, Parra HS, Privitera G, Motta F, Lanzafame S, Scaglione G, Longo A, Albanese V, Certo F.

Neurosurg Focus. 2014 Dec;37(6):E4. doi: 10.3171/2014.9.FOCUS14502.

PMID:
25434389
3.

Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.

Jastaniyah N, Murtha A, Pervez N, Le D, Roa W, Patel S, Mackenzie M, Fulton D, Field C, Ghosh S, Fallone G, Abdulkarim B.

Radiat Oncol. 2013 Feb 20;8:38. doi: 10.1186/1748-717X-8-38.

4.

Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma.

Sun MZ, Oh T, Ivan ME, Clark AJ, Safaee M, Sayegh ET, Kaur G, Parsa AT, Bloch O.

J Neurosurg. 2015 May;122(5):1144-50. doi: 10.3171/2014.9.JNS14193. Epub 2015 Mar 13.

PMID:
25768833
5.

Hypofractionated radiation therapy versus standard fractionated radiation therapy with concurrent temozolomide in elderly patients with newly diagnosed glioblastoma.

Wang TJC, Wu CC, Jani A, Estrada J, Ung T, Chow DS, Soun JE, Saad S, Qureshi YH, Gartrell R, Saadatmand HJ, Saraf A, Garrett MD, Grubb C, Isaacson SR, Cheng SK, Sisti MB, Bruce JN, Sheth SA, Lassman AB, Iwamoto FM, McKhann GM 2nd.

Pract Radiat Oncol. 2016 Sep-Oct;6(5):306-314. doi: 10.1016/j.prro.2015.12.001. Epub 2015 Dec 4.

PMID:
26952813
6.

Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.

Shields LB, Shelton BJ, Shearer AJ, Chen L, Sun DA, Parsons S, Bourne TD, LaRocca R, Spalding AC.

Radiat Oncol. 2015 Oct 31;10:222. doi: 10.1186/s13014-015-0527-0.

7.

Concurrent Chemoradiotherapy with Temozolomide Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients: A Retrospective Multicenter Observation Study in Korea.

Kim BS, Seol HJ, Nam DH, Park CK, Kim IH, Kim TM, Kim JH, Cho YH, Yoon SM, Chang JH, Kang SG, Kim EH, Suh CO, Jung TY, Lee KH, Kim CY, Kim IA, Hong CK, Yoo H, Kim JH, Kang SH, Kang MK, Kim EY, Kim SH, Chung DS, Hwang SC, Song JH, Cho SJ, Lee SI, Lee YS, Ahn KJ, Kim SH, Lim DH, Gwak HS, Lee SH, Hong YK.

Cancer Res Treat. 2017 Jan;49(1):193-203. doi: 10.4143/crt.2015.473. Epub 2016 Jun 27.

8.

Delaying standard combined chemoradiotherapy after surgical resection does not impact survival in newly diagnosed glioblastoma patients.

Louvel G, Metellus P, Noel G, Peeters S, Guyotat J, Duntze J, Le Reste PJ, Dam Hieu P, Faillot T, Litre F, Desse N, Petit A, Emery E, Voirin J, Peltier J, Caire F, Vignes JR, Barat JL, Langlois O, Menei P, Dumont SN, Zanello M, Dezamis E, Dhermain F, Pallud J; Club de Neuro-Oncologie of Société Française deNeurochirurgie.

Radiother Oncol. 2016 Jan;118(1):9-15. doi: 10.1016/j.radonc.2016.01.001. Epub 2016 Jan 11.

PMID:
26791930
9.

Prolonged Temozolomide Maintenance Therapy in Newly Diagnosed Glioblastoma.

Skardelly M, Dangel E, Gohde J, Noell S, Behling F, Lepski G, Borchers C, Koch M, Schittenhelm J, Bisdas S, Naumann A, Paulsen F, Zips D, von Hehn U, Ritz R, Tatagiba MS, Tabatabai G.

Oncologist. 2017 May;22(5):570-575. doi: 10.1634/theoncologist.2016-0347. Epub 2017 Mar 30.

10.

Long-term follow-up results of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastoma multiforme patients. The importance of MRI information in survival: Single-center experience.

Lukács G, Tóth Z, Sipos D, Csima M, Hadjiev J, Bajzik G, Cselik Z, Semjén D, Repa I, Kovács Á.

Ideggyogy Sz. 2018 Mar 30;71(3-04):95-103. doi: 10.18071/isz.71.0095.

PMID:
29889468
11.

Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.

Reddy K, Damek D, Gaspar LE, Ney D, Waziri A, Lillehei K, Stuhr K, Kavanagh BD, Chen C.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):655-60. doi: 10.1016/j.ijrobp.2012.01.035. Epub 2012 Apr 5.

PMID:
22483738
12.

The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.

Sher DJ, Henson JW, Avutu B, Hochberg FH, Batchelor TT, Martuza RL, Barker FG 2nd, Loeffler JS, Chakravarti A.

J Neurooncol. 2008 May;88(1):43-50. doi: 10.1007/s11060-008-9530-8. Epub 2008 Jan 30.

13.

Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study.

Navarria P, Pessina F, Tomatis S, Soffietti R, Grimaldi M, Lopci E, Chiti A, Leonetti A, Casarotti A, Rossi M, Cozzi L, Ascolese AM, Simonelli M, Marcheselli S, Santoro A, Clerici E, Bello L, Scorsetti M.

Oncotarget. 2017 Jun 28;8(40):67696-67708. doi: 10.18632/oncotarget.18809. eCollection 2017 Sep 15.

14.

Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors.

Mallick S, Gandhi AK, Joshi NP, Kumar A, Puri T, Sharma DN, Haresh KP, Gupta S, Julka PK, Rath GK, Sarkar C.

Indian J Med Paediatr Oncol. 2015 Apr-Jun;36(2):99-104. doi: 10.4103/0971-5851.158838.

15.

Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment.

Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, Lai A.

Int J Radiat Oncol Biol Phys. 2018 Apr 1;100(5):1195-1203. doi: 10.1016/j.ijrobp.2018.01.001. Epub 2018 Jan 6. Erratum in: Int J Radiat Oncol Biol Phys. 2019 Apr 1;103(5):1289.

16.

A Phase 2 Study of Concurrent Radiation Therapy, Temozolomide, and the Histone Deacetylase Inhibitor Valproic Acid for Patients With Glioblastoma.

Krauze AV, Myrehaug SD, Chang MG, Holdford DJ, Smith S, Shih J, Tofilon PJ, Fine HA, Camphausen K.

Int J Radiat Oncol Biol Phys. 2015 Aug 1;92(5):986-992. doi: 10.1016/j.ijrobp.2015.04.038. Epub 2015 Apr 30.

17.

Standard dose and dose-escalated radiation therapy are associated with favorable survival in select elderly patients with newly diagnosed glioblastoma.

Jackson WC, Tsien CI, Junck L, Leung D, Hervey-Jumper S, Orringer D, Heth J, Wahl DR, Spratt DE, Cao Y, Lawrence TS, Kim MM.

J Neurooncol. 2018 May;138(1):155-162. doi: 10.1007/s11060-018-2782-z. Epub 2018 Feb 1.

PMID:
29388034
18.

Impact of glycemia on survival of glioblastoma patients treated with radiation and temozolomide.

Tieu MT, Lovblom LE, McNamara MG, Mason W, Laperriere N, Millar BA, Ménard C, Kiehl TR, Perkins BA, Chung C.

J Neurooncol. 2015 Aug;124(1):119-26. doi: 10.1007/s11060-015-1815-0. Epub 2015 May 27.

19.

Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.

Iaccarino C, Orlandi E, Ruggeri F, Nicoli D, Torricelli F, Maggi M, Cerasti D, Pisanello A, Pedrazzi G, Froio E, Crafa P, D'Abbiero N, Michiara M, Ghadirpour R, Servadei F.

Clin Neurol Neurosurg. 2015 May;132:1-8. doi: 10.1016/j.clineuro.2015.01.029. Epub 2015 Feb 7.

PMID:
25723791
20.

Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.

Chen C, Damek D, Gaspar LE, Waziri A, Lillehei K, Kleinschmidt-DeMasters BK, Robischon M, Stuhr K, Rusthoven KE, Kavanagh BD.

Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):1066-74. doi: 10.1016/j.ijrobp.2010.07.021. Epub 2010 Oct 6.

PMID:
20932651

Supplemental Content

Support Center